Skip to main content

Author: Customer Service

Asante Gold Announces C$125 Million Bought Deal Private Placement, C$13.8 Million Non-Brokered Private Placement, Access to US$30 Million Senior Debt Accordion

Not for distribution to United States news wire services or for dissemination in the United States VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) — Asante Gold Corporation (TSX-V: ASE | GSE: ASG | OTCQX: ASGOF) (“Asante” or the “Company“) is pleased to announce that it has entered into an agreement with BMO Capital Markets (“BMO“), pursuant to which BMO has agreed to act as lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters (together with BMO, the “Underwriters“), in connection with a bought deal private placement of an aggregate of 78,125,000 common shares in the capital of the Company (“Common Shares“) at a price of C$1.60 per Common Share (the “Offering Price“) for aggregate gross proceeds of C$125,000,000 (the “Brokered...

Continue reading

Dragonfly Energy Announces 1-For-10 Reverse Stock Split

RENO, Nev., Dec. 16, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Thursday, December 18, 2025. Dragonfly Energy’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “DFLI” and under a new CUSIP number, 26145B 403. As a result of the reverse stock split, every ten pre-split shares of common stock outstanding will become one share of common stock. The par value of Dragonfly Energy’s common stock will remain unchanged at $0.0001 per share after the reverse stock split. The reverse stock split...

Continue reading

FTI Consulting Survey Shows Life Sciences Leaders’ Outlook Tempered by Concerns Around Fundraising, Policy Shifts and Cybersecurity Heading into 2026

Industry Leaders Point to Challenging Political and Economic Environment Key Legislation Expected to Impact Supply Chain and Drug Costs Recent M&A Momentum Offset by Challenging Fundraising Environment Artificial Intelligence (AI) Seen as Key Investment Area WASHINGTON, Dec. 16, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced findings from its fifth annual U.S. Healthcare & Life Sciences Industry Outlook 2026, which revealed that leaders are less optimistic about the state of the industry, down 9% from last year’s survey. The survey indicates that while optimism persists in some areas, industry leaders are navigating significant challenges within the capital markets, evolving political and regulatory landscapes, and have ongoing cybersecurity concerns. “As we look towards 2026, life sciences companies...

Continue reading

Caliber Selects StoneX for Added Trading and Custody for LINK Treasury

SCOTTSDALE, Ariz., Dec. 16, 2025 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today announced it has selected StoneX as an additional institutional platform for trading and custody in support of Caliber’s Digital Asset Treasury (DAT) Strategy. StoneX, through its Prime offering, is providing Caliber with access to deep liquidity and institutional-grade custody, using the same infrastructure trusted by some of the world’s largest financial institutions. “We are excited to be adding StoneX as a partner to support our digital asset treasury infrastructure,” said Chris Loeffler, Chief Executive Officer of Caliber, “Our goal is to present differentiated exposure to LINK through Caliber’s stock and StoneX brings Caliber an edge in LINK accumulation and trading, powered by...

Continue reading

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN™ rapamycin for angiokeratomas may be eligible for Accelerated Approval and Priority Review in the future, if applicable criteria are met Palvella plans to initiate a Phase 2 trial evaluating QTORIN™ rapamycin for clinically significant angiokeratomas in the second half of 2026 Angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality of life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients WAYNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical...

Continue reading

Brixton Metals Reports the Balance of its 2025 Drill Results at the Trapper Gold Target

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce updated and complete assay results from the Trapper Gold Target at its wholly owned Thorn Project in northwestern British Columbia. This release includes multi-element results for all remaining holes from the 2025 campaign, as well as updated intervals for previously reported drill holes where only gold was disclosed. A total of 6272m was drilled at the Trapper Target from 30 holes this season. The Trapper gold zone remains open for expansion. HighlightsGold and silver mineralization were intersected in drilling at the Trapper Gold Target, extending up to 1km away from the main mineralized zone, within the NW-SE trending gold-in-soil anomaly.Hole THN25-358 returned...

Continue reading

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™ DuloCore™ base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics,...

Continue reading

Envirotech Vehicles Unveils Exclusive AI Infrastructure Expansion Framework With AZIO AI

Proposed combination positions EVTV at the forefront of sovereign and emerging-market AI infrastructure, spanning data centers, enterprise compute, AI-powered agriculture, and drone-enabled systems, anchored by AZIO AI’s $50M+ active pipeline within its first two months of operation HOUSTON and NEWPORT BEACH, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) — via IBN — Envirotech Vehicles, Inc. (NASDAQ:EVTV) (“EVTV” or the “Company”) today announced that it has entered into an exclusive strategic acquisition framework with AZIO AI Corporation (www.azioai.ai), a rapidly scaling AI infrastructure company delivering high-performance compute, modular data-center solutions, and applied AI platforms for governments, institutions, and enterprises worldwide. The framework outlines a proposed combination that...

Continue reading

Energous’ PowerBridge Pro Gains EU Approval, Unlocking Wireless Power in Europe

Certification enables commercialization of Energous’ flagship wireless power transmitter across EU and UK markets SAN JOSE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) — Energous Corporation d/b/a Energous Wireless Power Solutions (NASDAQ: WATT), a leader in over-the-air (OTA) wireless power networks, today announced that its PowerBridge Pro Directional transmitter has received regulatory approval for deployment across the European Union. With this approval, Energous’ EU-certified portfolio now includes both PowerBridge Lite and Pro, enabling commercialization across all EU member states and the UK. The newly certified PowerBridge Pro delivers 2W conducted power with 39.5 dBi of EIRP – offering enterprises broader coverage and higher-performance at-a-distance wireless power. With dual-band approval for both lower and upper bands (865...

Continue reading

TDG Gold Delivers Transformational 2025 and Advances 2026 Growth Strategy with a Strong Treasury

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) — TDG Gold Corp. (TSXV: TDG | OTCQX: TDGGF) (the “Company” or “TDG”) is pleased to provide a year-end corporate update highlighting a year of significant operational, financial, and exploration achievements in 2025, while outlining a focused and well-funded strategy for continued growth in 2026. During 2025, TDG delivered a series of transformational milestones that materially advanced the Company’s scale, asset quality, and market profile. These achievements were driven by the successful discovery at Aurora West, the strategic acquisition of the Anyox Copper Project, and disciplined capital deployment across its portfolio of gold and copper assets. 2025 Highlights: Discovery, Scale, and Accretive Growth2025 marked a defining year for TDG, underscored by a more than 600%...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.